Czech Hizentra Noninterventional Study With Rapid Push:
Efficacy, Safety, Tolerability, and Convenience of Therapy With
20% Subcutaneous Immunoglobulin

J 2019

Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin

MILOTA, Tomas, Marketa BLOOMFIELD, Pavlina KRALICKOVA, Dalibor JILEK, Vitezslav NOVAK et. al.

Základní údaje

Originální název

Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin

Autoři

MILOTA, Tomas (203 Česká republika, garant), Marketa BLOOMFIELD (203 Česká republika), Pavlina KRALICKOVA (203 Česká republika), Dalibor JILEK (203 Česká republika), Vitezslav NOVAK (203 Česká republika), Jiří LITZMAN (203 Česká republika, domácí), Helena POSOVA (203 Česká republika), Lucie MRAZOVA (203 Česká republika), Jana POLONIOVA (203 Česká republika), Miroslav PRUCHA (203 Česká republika), Pavel ROZSIVAL (203 Česká republika), Vlasta RAUSCHOVA (203 Česká republika), Gunnar PHILIPP (203 Česká republika) a Anna SEDIVA (203 Česká republika)

Vydání

Clinical Therapeutics, BRIDGEWATER, Elsevier, 2019, 0149-2918

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.119

Kód RIV

RIV/00216224:14110/19:00112432

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.clinthera.2019.08.013

UT WoS

000503107700004

Klíčová slova anglicky

Nonmedical switch; Primary antibody deficiency; Rapid push; Subcutaneous immunoglobulin replacement therapy; Treatment satisfaction

Štítky

14110114, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 1. 2020 07:22, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: Immunoglobulin substitution therapy is an essential therapeutic approach for patients with primary antibody deficiencies. Different methods of administration, including intravenous immunoglobulin (WIG) or subcutaneous immunoglobulin (SCIG) preparations, provide effective and tolerable treatment and enable the adjustment of therapy to patients' needs. A new 20% SCIG represents a new therapeutic option and a new route of administration using rapid-push application. The aim of the Czech Hizentra Noninterventional Study With Rapid Push (CHHINSTRAP) is to evaluate patient satisfaction with as well as the tolerability and efficacy of nonmedical switch to 20% SCIG from previous treatment with WIG or SCIG and rapid push as a new way to administer SCIG. CHHINSTRAP is the first Phase W, noninterventional, open-label, prospective, multicentric study of this type conducted in Central and Eastern Europe. Methods: Primary end points, including efficacy, adverse effects, convenience of use, and overall satisfaction, were evaluated by Treatment Satisfaction Questionnaire for Medication version II. Secondary end points, such as serum IgG trough levels, infusion duration, number of application sites, frequency of infections, related hospital admissions, and antibiotic consumption, were obtained from patients at each follow-up visit. Findings: Together, 50 eligible patients with primary antibody deficiency were switched from SCIG or WIG to an equivalent dose of 20% SCIG and were followed up for 12 months during 5 consecutive visits. The results indicate that patients switched from previous WIG or SCIG preparations had significantly higher serum trough IgG levels and a lower incidence of infections and related events, such as hospital admissions or consumption of antibiotics. These findings were also reflected in gradually increasing convenience of use and overall satisfaction reported by patients. Apart from duration of application, no differences were found between patients previously receiving SCIG or WIG. Moreover, our study found a high level of safety of 20% SCIG rapid push, which was comparable to other preparations and application methods. (C) 2019 Elsevier Inc. All rights reserved.

Citovat

MILOTA, Tomas, Marketa BLOOMFIELD, Pavlina KRALICKOVA, Dalibor JILEK, Vitezslav NOVAK, Jiří LITZMAN, Helena POSOVA, Lucie MRAZOVA, Jana POLONIOVA, Miroslav PRUCHA, Pavel ROZSIVAL, Vlasta RAUSCHOVA, Gunnar PHILIPP a Anna SEDIVA. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin. Clinical Therapeutics. BRIDGEWATER: Elsevier, 2019, roč. 41, č. 11, s. 2231-2238. ISSN 0149-2918. Dostupné z: https://dx.doi.org/10.1016/j.clinthera.2019.08.013.

@article{1604796,
   author = {Milota, Tomas and Bloomfield, Marketa and Kralickova, Pavlina and Jilek, Dalibor and Novak, Vitezslav and Litzman, Jiří and Posova, Helena and Mrazova, Lucie and Poloniova, Jana and Prucha, Miroslav and Rozsival, Pavel and Rauschova, Vlasta and Philipp, Gunnar and Sediva, Anna},
   article_location = {BRIDGEWATER},
   article_number = {11},
   doi = {http://dx.doi.org/10.1016/j.clinthera.2019.08.013},
   keywords = {Nonmedical switch; Primary antibody deficiency; Rapid push; Subcutaneous immunoglobulin replacement therapy; Treatment satisfaction},
   language = {eng},
   issn = {0149-2918},
   journal = {Clinical Therapeutics},
   title = {Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin},
   url = {http://dx.doi.org/10.1016/j.clinthera.2019.08.013},
   volume = {41},
   year = {2019}
}

TY  - JOUR
ID  - 1604796
AU  - Milota, Tomas - Bloomfield, Marketa - Kralickova, Pavlina - Jilek, Dalibor - Novak, Vitezslav - Litzman, Jiří - Posova, Helena - Mrazova, Lucie - Poloniova, Jana - Prucha, Miroslav - Rozsival, Pavel - Rauschova, Vlasta - Philipp, Gunnar - Sediva, Anna
PY  - 2019
TI  - Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin
JF  - Clinical Therapeutics
VL  - 41
IS  - 11
SP  - 2231-2238
EP  - 2231-2238
PB  - Elsevier
SN  - 01492918
KW  - Nonmedical switch
KW  - Primary antibody deficiency
KW  - Rapid push
KW  - Subcutaneous immunoglobulin replacement therapy
KW  - Treatment satisfaction
UR  - http://dx.doi.org/10.1016/j.clinthera.2019.08.013
L2  - http://dx.doi.org/10.1016/j.clinthera.2019.08.013
N2  - Purpose: Immunoglobulin substitution therapy is an essential therapeutic approach for patients with primary antibody deficiencies. Different methods of administration, including intravenous immunoglobulin (WIG) or subcutaneous immunoglobulin (SCIG) preparations, provide effective and tolerable treatment and enable the adjustment of therapy to patients' needs. A new 20% SCIG represents a new therapeutic option and a new route of administration using rapid-push application. The aim of the Czech Hizentra Noninterventional Study With Rapid Push (CHHINSTRAP) is to evaluate patient satisfaction with as well as the tolerability and efficacy of nonmedical switch to 20% SCIG from previous treatment with WIG or SCIG and rapid push as a new way to administer SCIG. CHHINSTRAP is the first Phase W, noninterventional, open-label, prospective, multicentric study of this type conducted in Central and Eastern Europe. Methods: Primary end points, including efficacy, adverse effects, convenience of use, and overall satisfaction, were evaluated by Treatment Satisfaction Questionnaire for Medication version II. Secondary end points, such as serum IgG trough levels, infusion duration, number of application sites, frequency of infections, related hospital admissions, and antibiotic consumption, were obtained from patients at each follow-up visit. Findings: Together, 50 eligible patients with primary antibody deficiency were switched from SCIG or WIG to an equivalent dose of 20% SCIG and were followed up for 12 months during 5 consecutive visits. The results indicate that patients switched from previous WIG or SCIG preparations had significantly higher serum trough IgG levels and a lower incidence of infections and related events, such as hospital admissions or consumption of antibiotics. These findings were also reflected in gradually increasing convenience of use and overall satisfaction reported by patients. Apart from duration of application, no differences were found between patients previously receiving SCIG or WIG. Moreover, our study found a high level of safety of 20% SCIG rapid push, which was comparable to other preparations and application methods. (C) 2019 Elsevier Inc. All rights reserved.
ER  -

MILOTA, Tomas, Marketa BLOOMFIELD, Pavlina KRALICKOVA, Dalibor JILEK, Vitezslav NOVAK, Jiří LITZMAN, Helena POSOVA, Lucie MRAZOVA, Jana POLONIOVA, Miroslav PRUCHA, Pavel ROZSIVAL, Vlasta RAUSCHOVA, Gunnar PHILIPP a Anna SEDIVA. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20\%{} Subcutaneous Immunoglobulin. \textit{Clinical Therapeutics}. BRIDGEWATER: Elsevier, 2019, roč.~41, č.~11, s.~2231-2238. ISSN~0149-2918. Dostupné z: https://dx.doi.org/10.1016/j.clinthera.2019.08.013.

Podrobný výpis o publikaci